Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies
{{output}}
The discovery of activating BRAF mutations in ∼50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease. In this commentary, we review the latest research delineating the role of mutant BRAF in melanoma i... ...